Related references
Note: Only part of the references are listed.Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
Dana L. Casey et al.
CANCER (2019)
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Gianni Bisogno et al.
LANCET ONCOLOGY (2019)
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group
Emily Hibbitts et al.
CANCER MEDICINE (2019)
Rhabdomyosarcoma
Stephen X. Skapek et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Fusion Status in Patients With Lymph Node-Positive (N1) Alveolar Rhabdomyosarcoma Is a Powerful Predictor of Prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego et al.
CANCER (2018)
Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma
Emily Z. Keung et al.
EJSO (2018)
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno et al.
LANCET ONCOLOGY (2018)
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Douglas S. Hawkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
Erin R. Rudzinski et al.
PEDIATRIC BLOOD & CANCER (2017)
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Brenda J. Weigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group
Michael A. Arnold et al.
PEDIATRIC BLOOD & CANCER (2016)
Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?
M. Ben Arush et al.
EUROPEAN JOURNAL OF CANCER (2015)
The Cyclophosphamide Equivalent Dose as an Approach for Quantifying Alkylating Agent Exposure: A Report From the Childhood Cancer Survivor Study
Daniel M. Green et al.
PEDIATRIC BLOOD & CANCER (2014)
Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee
Aaron R. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report
Stephen X. Skapek et al.
PEDIATRIC BLOOD & CANCER (2013)
Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study
Odile Oberlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group
David A. Rodeberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy
Julia C. Chisholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients
Iyad Sultan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups
Odile Oberlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group
Jane L. Meza et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy
Philippe E. Spiess et al.
CANCER (2006)
European Intergroup Studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: Final results and analysis of prognostic factors
M Carli et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
D Joshi et al.
PEDIATRIC BLOOD & CANCER (2004)
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma:: A report from the children's oncology group
PHB Sorensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for intergroup rhabdomyosarcoma study V
RB Raney et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2001)
Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: A preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997)
HL Neville et al.
JOURNAL OF PEDIATRIC SURGERY (2000)
Share Paper
